Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Study answer

What this study found

Sodium butyrate did not improve intestinal inflammation, kidney parameters, glycemic control, or other measured biomarkers versus placebo. Fecal calprotectin did not differ significantly at 12 weeks (ANCOVA p = 0.24), and urinary albumin-creatinine ratio (p = 0.69), estimated glomerular filtration rate (p = 0.30), hs-CRP (p = 0.13), serum lipopolysaccharide (p = 0.093), and HbA1c (p = 0.32) were also not significantly changed. Other fecal markers, including IAP activity/protein, fecal butyrate, acetate, propionate, valerate, and immunoglobulins, were likewise not significantly different. The…

Study & population

Randomized, double-blind, placebo-controlled trial in adults with type 1 diabetes, albuminuria, and intestinal inflammation.

Intervention

Oral sodium butyrate was given at 3.6 g/day for 12 weeks, delivered as delayed-release capsules with sodium alginate.

Key limitation

The trial was relatively small and short, which limits power to detect modest effects and longer-term renal or metabolic changes.

View full study detailsView sourceOpen PDF

Original abstract